乳房再造的成本及其对基于 episodes 的捆绑支付模式的影响
该研究基于 MarketScan 商业保险数据库 2009–2016 年 15,377 例即刻乳房再造女性,分析癌症治疗、合并症、修整手术和并发症对 30 天至 2 年各 episode 成本的影响,发现辅助治疗显著增加 1 年成本,多数修整和并发症发生在 1 年内,建议按医疗与外科分别捆绑并校正术式、癌症治疗和合并症,1 年时间窗或可最优捕获再造事件与并发症。
要点
- 辅助治疗显著增加 1 年成本:组织扩张器 $39,978、直接植入 $34,365、自体 $29,226(均 p<0.001)。
- 1 年时 76% 患者已行组织扩张器交换、81% 行修整手术、87% 并发症已发生。
- 合并症、修整手术和并发症在所有 episode 场景均增加成本。
核心结论
- 基于 episode 的捆绑支付应分别设置医疗与外科捆绑,并按术式、癌症治疗和合并症校正,以限制对再造可及性的不利影响。
- 1 年时间窗可能最优捕获再造事件和并发症。
研究设计与样本
- 回顾性队列研究,使用 MarketScan 商业索赔与 encounters 数据库 2009–2016 年数据。
- 纳入即刻乳房再造女性,要求再造前 3 个月和再造后 24 个月连续参保。
- 分析队列共 15,377 例,其中组织扩张器 11,592 例(75%)、直接植入 1,279 例(8%)、自体再造 2,506 例(16%)。
- 在预设 episode(30 天、90 天、1 年、2 年)内计算总成本,多变量模型评估成本预测因素。
主要发现
- 辅助治疗增加 1 年成本:组织扩张器 $39,978(p<0.001)、直接植入 $34,365(p<0.001)、自体 $29,226(p<0.001)。
- 1 年时 76% 患者已行组织扩张器交换,81% 行修整手术,87% 并发症已发生。
- 合并症、修整手术和并发症在所有 episode 场景均增加成本。
临床怎么用
- 设计捆绑支付时需分别考虑医疗与外科服务,并按术式、癌症治疗和合并症进行风险校正。
- 可考虑采用 1 年时间窗作为捆绑支付 episode 时长,以覆盖多数修整手术和并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implementation of payment reform for breast reconstruction following mastectomy demands a comprehensive understanding of costs related to the complex process of reconstruction. Bundled payments for services to women with breast cancer may profoundly impact reimbursement and access to breast reconstruction. The authors' objectives were to determine the contribution of cancer therapies, comorbidities, revisions, and complications to costs following immediate reconstruction and the optimal duration of episodes to incentivize cost containment for bundled payment models. METHODS: The cohort was composed of women who underwent immediate breast reconstruction between 2009 and 2016 from the MarketScan Commercial Claims and Encounters database. Continuous enrollment for 3 months before and 24 months after reconstruction was required. Total costs were calculated within predefined episodes (30 days, 90 days, 1 year, and 2 years). Multivariable models assessed predictors of costs. RESULTS: Among 15,377 women in the analytic cohort, 11,592 (75 percent) underwent tissue expander, 1279 (8 percent) underwent direct-to-implant, and 2506 (16 percent) underwent autologous reconstruction. Adjuvant therapies increased costs at 1 year [tissue expander, $39,978 (p < 0.001); direct-to-implant, $34,365 (p < 0.001); and autologous, $29,226 (p < 0.001)]. At 1 year, most patients had undergone tissue expander exchange (76 percent) and revisions (81 percent), and a majority of complications had occurred (87 percent). Comorbidities, revisions, and complications increased costs for all episode scenarios. CONCLUSIONS: Episode-based bundling should consider separate bundles for medical and surgical care with adjustment for procedure type, cancer therapies, and comorbidities to limit the adverse impact on access to reconstruction. The authors' findings suggest that a 1-year time horizon may optimally capture reconstruction events and complications.
引用
- Berlin NL, Chung KC, Matros E, et al. The Costs of Breast Reconstruction and Implications for Episode-Based Bundled Payment Models. Plast Reconstr Surg. 2020. PMID: 33234949. doi:10.1097/PRS.0000000000007329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。